Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 3/20 | 0.61 |
| ▸ | F2 | P00734 | 2/20 | 0.61 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.61 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.61 |
| ▸ | PLAU | P00749 | 1/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.61 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.61 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.61 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 1/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | S100B | P04271 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | AOC1 | P19801 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548439 | 0.98 | PRSS1 (0.60) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL549185 | 0.94 | TMPRSS2 (0.60) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL6510086 | 0.92 | TP53 (0.59) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL5543953 | 0.92 | PRMT1 (0.53) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL15020066 | 0.92 | TP53 (0.59) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL7341007 | 0.92 | TP53 (0.59) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL8718224 | 0.90 | TP53 (0.57) | PRSS1GAA | |
| SCHEMBL6407420 | 0.89 | MMP1 (0.56) | TMPRSS2CYP2D6PRSS1GAA | |
| SCHEMBL20332718 | 0.89 | TMPRSS2 (0.55) | PRMT1F2ST14TMPRSS2PLAU | |
| SCHEMBL409427 | 0.87 | NR1I2 (0.53) | PRMT1F2ST14TMPRSS2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-20010044468-A1 | Benzamidoxime prodrugs as antipneumocystic agents | HALL JAMES E (US) | 2001-11-22 | — | — | US | claimed |
| US-6214883-B1 | BIS//N-HYDROXYAMIDINO/PHENOXY OR -THIO/ALKANES REDUCED AFTER ORAL ADMINISTRATION TO THE CORRESPONDING MONO- OR BISAMIDINES | THE GEORGIA STATE UNIVERSITY | 2001-04-10 | — | — | US | claimed |
| EP-0861071-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-02 | — | — | EP | claimed |
| US-5723495-A | TREATMENT OF PNEUMONIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-03-03 | — | — | US | claimed |
| WO-1997017949-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-22 | — | — | WO | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-5723495-A | TREATMENT OF PNEUMONIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997017949-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | PRMT1 2728/4885F2 4176/4885ST14 844/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | PRMT1 2584/4885F2 2085/4885ST14 508/4885 |
| US-20010044468-A1 | Benzamidoxime prodrugs as antipneumocystic agents | BHMT, BBOX1, BCHE | PRMT1 500/4885F2 3064/4885ST14 2358/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | PRMT1 1095/4885F2 3907/4885ST14 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.